Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells $49,840.84 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 21,119 shares of the firm’s stock in a transaction on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the transaction, the insider now directly owns 464,582 shares of the company’s stock, valued at $1,096,413.52. The trade was a 4.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

John Nuss also recently made the following trade(s):

• On Thursday, December 19th, John Nuss sold 13,161 shares of Ventyx Biosciences stock. The shares were sold at an average price of $2.26, for a total value of $29,743.86.

Ventyx Biosciences Trading Down 1.8 %

Shares of Ventyx Biosciences stock opened at $2.19 on Thursday. The company has a market cap of $154.86 million, a P/E ratio of -0.93 and a beta of 0.48. The business has a 50-day moving average price of $2.28 and a two-hundred day moving average price of $2.30. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48.

Analyst Ratings Changes

A number of equities research analysts have commented on VTYX shares. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. Oppenheimer reissued an “outperform” rating and set a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Investors Weigh In On Ventyx Biosciences

Several large investors have recently added to or reduced their stakes in VTYX. Deerfield Management Company L.P. Series C boosted its holdings in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after buying an additional 2,287,570 shares in the last quarter. Sio Capital Management LLC lifted its position in shares of Ventyx Biosciences by 153.2% during the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after acquiring an additional 1,193,024 shares during the period. Vestal Point Capital LP grew its holdings in Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $3,760,000 after purchasing an additional 410,000 shares during the period. Geode Capital Management LLC increased its stake in Ventyx Biosciences by 5.9% in the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after purchasing an additional 77,350 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after purchasing an additional 9,783 shares during the period. Institutional investors and hedge funds own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.